Norrsken VC
VC Fund
Stockholm, Sweden
Norrsken VC is a Stockholm-based impact VC fund investing in start-ups solving the world's biggest problems while building massive businesses
- Total investments:
- 110
- Last investment:
- Lead investor:
- 32%
- Fund size:
- $346M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Norrsken VC invests in
Stages Norrsken VC invests in
Countries Norrsken VC invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 6 contacts → | |||
Round size
- Seed
- $893k–$14M
- Series A
- $4.4M–$52M
- Venture - Series Unknown
- $1.1M–$156M
Investment Focus
Industry
- Software 15 (14%)
- Artificial Intelligence 10 (9%)
- Health Care 9 (8%)
- Food and Beverage 9 (8%)
- CleanTech 8 (7%)
Stage
- Seed 38 (35%)
- Series A 28 (25%)
- Venture - Series Unknown 13 (12%)
- Series B 8 (7%)
- Pre-Seed 5 (5%)
Country
- Sweden 28 (25%)
- United Kingdom 10 (9%)
- Germany 9 (8%)
- France 5 (5%)
- United States 3 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
David Frykman
Founding General Partner
|
Founding General Partner | Total investments: 5 | Find email | |
Tove Larsson
General Partner
|
General Partner | Total investments: 14 | Find email | |
Agate Freimane
General Partner
|
General Partner | Total investments: 7 | Find email | |
Christoffer Nilsson
Venture Lead and Head of Business Development
|
Venture Lead and Head of Business Development | Total investments: 0 | Find email | |
Clara Lindh Bergendorff
Venture Partner
|
Venture Partner | Total investments: 4 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| All the health information we need is within us. Just below the skin. SAVA is redefining the way people interact with their health by developing the most advanced biosensing technology science has to offer, capable of accessing bodily information in a painless, real-time and affordable way. | $36M / Series B / Oct 09, 2026 | ||
| Vocca provides AI powered voice agents for healthcare centers to handle calls, bookings, and reminders, improving the patient experience. | $20M / Series A / Oct 06, 2026 | ||
| Verse helps large energy buyers Connect, Contain, and Control their global power portfolios: connect to the grid faster leveraging flexibility; contain energy cost and risk with real-time analytics and strategic procurement; and control assets to maximize portfolio value through real-time optimization. Verse team blends deep energy-market expertisewith modern software engineering and product design to deliver usable, scalable tools to manage power costs and risks. | $54M / Series B / Jun 18, 2026 | ||
| Endra is a software platform for mechanical, electrical, and plumbing (MEP) engineering that automates the design, modeling, and documentation of building systems. The platform generates 2D and 3D models, calculations, schedules, diagrams, and other engineering documentation from architectural and building design inputs. It supports disciplinessuch as electrical, fire alarm, HVAC, plumbing, and sprinkler system design, and integrates with Autodesk Revit and common CAD and BIM file formats. Endra uses artificial intelligence, simulation, and computational methods to assist with tasks such as system layout, cable routing, device placement, and documentation generation while helping engineers comply with applicable design standards and regulations. The platform is designed for MEP engineers and engineering firms seeking to reduce manual design and documentation work across construction projects. | $50M / Series A / Jun 01, 2026 | ||
| Biorce is an innovating HealthAI startup committed to transforming drug development through the use of artificial intelligence. | $52M / Series A / Feb 02, 2026 | ||
| Oviva is digitizing the treatment of type 2 diabetes and obesity through a unique behavior change platform.They have developed unique, personalised behaviour change programmes that combine smartphone app and learning portals to support dietitian-led behaviour change for conditions such as type 2 diabetes and complex obesity. Their approach allowspatients to achieve a better health outcome without having to attend clinic appointments, whilst saving health systems significant sums by preventing the development of complications related to these health conditions.Oviva was founded in 2013 and is based in Altendorf (Switzerland) with offices in Zurich (Switzerland), London (United Kingdom), and Berlin (Germany). | $233.7M / Series D / Jan 22, 2026 | ||
| Oviva is digitizing the treatment of type 2 diabetes and obesity through a unique behavior change platform.They have developed unique, personalised behaviour change programmes that combine smartphone app and learning portals to support dietitian-led behaviour change for conditions such as type 2 diabetes and complex obesity. Their approach allowspatients to achieve a better health outcome without having to attend clinic appointments, whilst saving health systems significant sums by preventing the development of complications related to these health conditions.Oviva was founded in 2013 and is based in Altendorf (Switzerland) with offices in Zurich (Switzerland), London (United Kingdom), and Berlin (Germany). | Secondary Market / Jan 22, 2026 | ||
| Terralayr uses software to collect energy grid-scale storage, which will be required as we strive to make renewable energy more efficient and lucrative. | $130.4M / Series A / Jan 19, 2026 | ||
| Ankar AI operates as a next-generation AI Intellectual Property platform. | $20M / Series A / Dec 16, 2025 | ||
| All the health information we need is within us. Just below the skin. SAVA is redefining the way people interact with their health by developing the most advanced biosensing technology science has to offer, capable of accessing bodily information in a painless, real-time and affordable way. | $18.8M / Series A / Jul 30, 2025 | ||
| See all 110 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Norrsken VC invest in?
Norrsken VC invests primarily in Software, Artificial Intelligence and Health Care startups, most often at Seed and Series A stage. Most of the 110 investments tracked by Shizune back companies in Sweden. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Norrsken VC invest in?
Norrsken VC typically joins rounds of $893k–$14M at Seed, $4.4M–$52M at Series A and $1.1M–$156M at Venture - Series Unknown. These are whole funding-round sizes, not Norrsken VC's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Norrsken VC took part in.
How do I contact Norrsken VC?
Public channels for Norrsken VC include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Norrsken VC?
The team at Norrsken VC includes David Frykman (Founding General Partner), Tove Larsson (General Partner) and Agate Freimane (General Partner), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
